The metabolic effect of antenatal corticosteroid therapy

The use of antenatal dexamethasone to mature the fetal lung in pregnancies likely to deliver before 34 weeks is almost universal, It reduces the incid ence of respiratory distress syndrome in the newborn and results in an over all improvement in neonatal morbidity and mortality. Although considered to be generally safe, there are concerns about adverse maternal and fetal eff ects. In a series of studies, we have found that antenatal dexamethasone ad ministration is associated with reduced placental hormone production and ma ternal bone formation, impaired glucose tolerance and altered function of t he hypothalamic-pituitary-adrenal axis. In this article, we have compared o ur data with other reports in the human and reviewed the relevant animal da ta. We conclude that further studies on the long-term effects of antenatal dexamethasone therapy in the human are warranted with particular emphasis o n the long-term effects on the fetus.